PGNX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PGNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Progenics Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2020 was $30.61 Mil. Progenics Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2020 was $98.34 Mil. Therefore, Progenics Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Mar. 2020 was 0.31.
The historical rank and industry rank for Progenics Pharmaceuticals's Equity-to-Asset or its related term are showing as below:
The historical data trend for Progenics Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Progenics Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.69 | 0.53 | 0.44 | 0.60 | 0.39 |
Progenics Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.51 | 0.48 | 0.43 | 0.39 | 0.31 |
For the Biotechnology subindustry, Progenics Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Progenics Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Progenics Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Progenics Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2019 is calculated as
Equity to Asset (A: Dec. 2019 ) | = | Total Stockholders Equity | / | Total Assets |
= | 46.553 | / | 119.47 | |
= | 0.39 |
Progenics Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Mar. 2020 is calculated as
Equity to Asset (Q: Mar. 2020 ) | = | Total Stockholders Equity | / | Total Assets |
= | 30.613 | / | 98.344 | |
= | 0.31 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Progenics Pharmaceuticals (NAS:PGNX) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Asha Das | officer: Chief Medical Officer | C/O PROGENICS PHARMACEUTICALS, INC., 1 WORLD TRADE CENTER, 47TH FL, SUITE J, NEW YORK NY 10007 |
Ann L. Macdougall | director | C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401 |
Karen Jean Ferrante | director | 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818 |
Heinz Christoph Maeusli | director | SCHUETZENWEG 3, ENGELBURG V8 9032 |
Gerard Ber | director | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Eric J Ende | director | C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921 |
Bradley L Campbell | director | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Balaji Venkataraman | 10 percent owner, other: See Explanation of Responses | FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076 |
Virinder Nohria | 10 percent owner, other: See Explanation of Responses | 1055 POWERS PLACE, SUITE B, ALPHARETTA GA 30009 |
Nicole Williams | director | |
David A Scheinberg | director | 325 CENTRAL PARK W, APT 38, NEW YORK NY 10025 |
Michael D Kishbauch | director | 18 CHERRYVILLE RD, FLEMINGTON NJ 08822 |
Broadfin Healthcare Master Fund Ltd | 10 percent owner | C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108 |
Kevin Kotler | 10 percent owner | C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Capital, Llc | 10 percent owner | 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By Marketwired Marketwired • 12-23-2019
By PRNewswire PRNewswire • 10-03-2019
By Marketwired Marketwired • 10-21-2019
By Marketwired Marketwired • 12-23-2019
By Marketwired Marketwired • 10-23-2019
By Marketwired Marketwired • 12-12-2019
By Marketwired Marketwired • 05-07-2020
By Marketwired Marketwired • 11-09-2019
By Marketwired Marketwired • 10-17-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.